Podcasts about improve outcomes

This activity was supported by an educational grant from Novartis. Please go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://academiccme.com/courses/CCRSjDPod/ and complete the evaluation to receive your CE/CME Credit. Credit is available through June 7, 2027

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this special episode recorded live at the American Diabetes Association (ADA) Scientific Sessions 2026 in New Orleans, Louisiana, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Trang Ly, PhD, MBBS, senior vice president and Chief Medical Officer at Insulet, to discuss the continued evolution of automated insulin delivery (AID) technology and emerging developments across the Omnipod platform. To begin the episode, Ly first reviews updates to Omnipod 5, focusing on enhancements aimed at increasing time in automated mode and improving glucose management. She explains that user feedback identified opportunities to support lower glucose targets and reduce interruptions related to system alerts. Data from real-world evidence and computer simulations suggest that lowering the glucose target from 110 to 100 mg/dL may lead to meaningful improvements in time in range and time in tight range without increasing hypoglycemia risk.The group discusses early clinical experience with these enhancements, including findings from users who transitioned to the updated system. Ly highlights that even a highly engaged population already using lower targets experienced additional improvements, including a 2% increase in time in range and a 5% increase in time in tight range over a short period of use. The conversation emphasizes the importance of making these improvements broadly available rather than waiting for routine follow-up visits, particularly given the potential benefits without additional safety concerns.The discussion then turns to Omnipod 6, with Ly sharing newly presented clinical trial data evaluating the next-generation system. She describes the study design, which enrolled users already achieving strong glycemic control on Omnipod 5 and assessed whether further intensification through algorithm improvements could safely provide additional benefits. The results demonstrated a 4% improvement in time in range and up to a 7% increase in time in tight range, with particularly notable improvements among individuals with type 1 diabetes aged 14 years and older.Ly explains that Omnipod 6 builds on previous technology through changes to the core algorithm, allowing the system to deliver more insulin when users do not bolus consistently. The panel explores how this approach may reduce the burden of diabetes management by allowing the algorithm to take on more responsibility while maintaining glycemic control. They discuss the potential psychological benefits of reducing the daily demands placed on people with diabetes, especially as sensor accuracy and automation continue to improve.The conversation also highlights future opportunities for AID in type 2 diabetes. Ly shares early feasibility data from a fully closed-loop system designed specifically for individuals with type 2 diabetes, emphasizing its simplified approach without requiring traditional pump programming or meal bolusing. In this study, participants experienced improvements in time in range, demonstrating the potential for automated insulin delivery to reach broader populations.Isaacs and Bellini discuss the need to reconsider barriers to insulin pump adoption in type 2 diabetes and recognize AID as an accessible option for patients who may benefit. Ly emphasizes that technology should support people across different levels of engagement, offering both highly customizable systems for those seeking intensive management and simpler automated approaches for those looking to reduce daily treatment demands.The episode concludes with a discussion of the future of diabetes technology, including improved connectivity, expanded device flexibility, and continued integration with complementary therapies such as GLP-1 receptor agonists. Ly underscores that innovation should not only improve clinical outcomes but also reduce the burden of care, allowing people with diabetes to spend less time managing their condition and more time living their lives.Editors' Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Ly reports a disclosure with Insulet.References1: Insulet. Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care. June 6, 2026. Accessed June 7, 2026. https://investors.insulet.com/news/news-details/2026/Insulet-Reveals-New-Data-Supporting-Breakthrough-Omnipod-6-and-Fully-Closed-Loop-AID-Systems-Designed-to-Improve-Outcomes-Reduce-Effort-and-Unlock-Barriers-to-Care/default.aspx

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NJM865. CME/MOC/AAPA/IPCE credit will be available until May 28, 2027.ReiNForcing Care Pathways in NF1-PN: Solutions to Improve Outcomes Across the Patient Journey With MEK Inhibition and Shared-Care Models In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Neurofibromatosis Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Alexion, AstraZeneca Rare Disease and SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Trisha Wise-Draper, MD, PhD - Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Cancer immunotherapy has transformed the treatment landscape for many advanced cancers over the past decade. Drugs targeting the PD-1 and PD-L1 pathways are now widely used across several tumor types, helping the immune system recognize and attack cancer cells more effectively. However, researchers are still working to understand how beneficial these therapies may be when used earlier in the disease course, particularly after surgery in patients with high-risk solid tumors. A research paper on this topic was published in Volume 17 of Oncotarget titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.” Full blog - https://www.oncotarget.org/2026/05/20/immune-checkpoint-inhibitors-may-improve-outcomes-in-high-risk-solid-tumors/ Paper DOI - https://doi.org/10.18632/oncotarget.28855 Correspondence to - Dhai Almuteri - d.almuteri@qu.edu.sa Abstract video - https://www.youtube.com/watch?v=4Ce07bHfjB4 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28855 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PD-1, PD-L1, adjuvant immunotherapy, solid tumor To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

With Maria Generosa Crespo-Leiro, Eduardo Barge-Caballero and David Couto-Mallon, University Hospital A Coruna, A Coruna - Spain. Link to paper Link to editorial

Achieving near-complete reperfusion in medium vessel occlusions (MeVO) is linked to smaller final infarct volumes.  However, this did not translate into a statistically significant shift in 90-day functional independence.   In this episode,  JNIS Editor-in-Chief, Dr. Michael Chen, and Professor Johanna Ospel (1) discuss the post-hoc analysis of the ESCAPE-MeVO trial, titled "Reperfusion grade and clinical outcome following medium vessel occlusion thrombectomy in the Endovascular Treatment to Improve Outcomes for Medium Vessel Occlusion trial".  Please subscribe to the JNIS podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/4aZmlpT) or Spotify (https://spoti.fi/3UKhGT5). We'd love to hear your feedback on social media - @JNIS_BMJ. (1) Clinical Associate Professor at the University of Calgary and Senior Lecturer at the University of Basel. The JNIS Podcast is produced by Letícia Amorim, and is edited by Pritesh Kapadia.

Tom Kim, Chief Medical Officer at Sound Long-Term Care Management, discusses the role of accountable care organizations, ACOs, in improving healthcare for the long-term care population. The unique complexities and challenges of these patients include multiple medical conditions, frequent hospitalizations, and fragmented care.  By using predictive analytics, telemedicine, and value-based care principles to deliver more coordinated care, patients are avoiding hospitalizations, receiving higher-quality care, and experiencing reduced costs. Tom explains, "So, in essence, an accountable care organization (ACO) is a group of healthcare providers that come together with a commitment to Medicare to improve the quality of care for the Medicare beneficiaries they serve and to decrease the cost of care for that population. And it's a way to really better coordinate care for those residents or for those Medicare beneficiaries to really receive the best outcome possible."   "Yes, so in the fee-for-service world, there is a lot of focus, at least from a provider standpoint, on volume. So you're really focused on seeing as many patients as you can. In a value-based care model, we're really moving away from the volume model toward one focused more on quality. So, instead of being rewarded for high volume, you're being rewarded as a provider for the quality of care you provide. And not only is this beneficial to the provider, but it's also beneficial to the patients. So, there's having more time with their provider, receiving better care, and hopefully avoiding unnecessary or avoidable care. And so it's really a win across the board, from both a provider and a patient standpoint."  "Our patient population tends to be more complex with more medical problems. They tend to be hospitalized more often. They tend to rely on others to make healthcare decisions and closer to the end of life. And so, care is really different from those who are still living at home and in the community. And on top of that, in terms of the long-term care space, and why it's so challenging is that you just kind of mentioned it a little bit, is that the population is aging."   #SLTCM #ACO #AccountableCareOrganizations #AccountableCare #LongTermCare #ValueBasedCare #HealthcareInnovation #Telemedicine #SeniorCare #HealthcareLeadership #PatientCare #HealthTech #Medicare sltcm.soundphysicians.com Download the transcript here

Tom Kim, Chief Medical Officer at Sound Long-Term Care Management, discusses the role of accountable care organizations, ACOs, in improving healthcare for the long-term care population. The unique complexities and challenges of these patients include multiple medical conditions, frequent hospitalizations, and fragmented care.  By using predictive analytics, telemedicine, and value-based care principles to deliver more coordinated care, patients are avoiding hospitalizations, receiving higher-quality care, and experiencing reduced costs. Tom explains, "So, in essence, an accountable care organization (ACO) is a group of healthcare providers that come together with a commitment to Medicare to improve the quality of care for the Medicare beneficiaries they serve and to decrease the cost of care for that population. And it's a way to really better coordinate care for those residents or for those Medicare beneficiaries to really receive the best outcome possible."   "Yes, so in the fee-for-service world, there is a lot of focus, at least from a provider standpoint, on volume. So you're really focused on seeing as many patients as you can. In a value-based care model, we're really moving away from the volume model toward one focused more on quality. So, instead of being rewarded for high volume, you're being rewarded as a provider for the quality of care you provide. And not only is this beneficial to the provider, but it's also beneficial to the patients. So, there's having more time with their provider, receiving better care, and hopefully avoiding unnecessary or avoidable care. And so it's really a win across the board, from both a provider and a patient standpoint."  "Our patient population tends to be more complex with more medical problems. They tend to be hospitalized more often. They tend to rely on others to make healthcare decisions and closer to the end of life. And so, care is really different from those who are still living at home and in the community. And on top of that, in terms of the long-term care space, and why it's so challenging is that you just kind of mentioned it a little bit, is that the population is aging."   #SLTCM #ACO #AccountableCareOrganizations #AccountableCare #LongTermCare #ValueBasedCare #HealthcareInnovation #Telemedicine #SeniorCare #HealthcareLeadership #PatientCare #HealthTech #Medicare sltcm.soundphysicians.com Listen to the podcast here

In this episode, Alexandra Anderson, Head of Health Plan Sales & Partnerships at Color, explores how proactive, personalized screening and integrated care pathways can improve early cancer detection and reduce total cost of care for cancer. She shares insights on Color's approach to identifying risk & closing screening gaps, increasing member engagement, and the importance of timely, proactive interventions along the cancer care continuum.This episode is sponsored by Color.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to share industry updates and Mayo Clinic's test development success in 2025. Later, Dr. Pritt welcomes Janelle Santos, M.D., a maternal-fetal medicine specialist at Mayo Clinic, to discuss how she uses a preeclampsia test to care for her patients.Public policy insights for 2026 (00:34): Dr. Bill Morice shares insights on reimbursement and AI-related policy developments following an association meeting in Washington, D.C. An unprecedented year for test development (04:45): Discover how Mayo Clinic's record year for test development delivers value to Mayo Clinic's patients and Mayo Clinic Laboratories' clients.Novel preeclampsia testing (08:13): Learn how new clinical testing helps physicians improve outcomes for women at risk for preeclampsia and their babies.Note: Information in this post was accurate at the time of its posting.Resources4 steps to establishing a new approach to innovation Innovation beyond the bench: Translating science into better diagnostics and outcomesPreeclampsia: Empowering confident decision-making through preeclampsia risk assessmentAssay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. Preeclampsia sFlt-1/PIGF Ratio, Serum (Mayo ID: PERA)

Join commit to 6 hereWhatsapp Emma here

Send a textIn this Journal Club episode, Ben and Daphna review the highly anticipated TREOCAPA trial results exploring the prophylactic use of acetaminophen for PDA closure in extremely preterm infants. They break down the study's tailored dosing regimens, safety outcomes like cholestasis, and discuss why achieving a higher rate of early ductal closure didn't necessarily translate to improved survival without severe morbidity. Plus, they share a nod to recent Neo Conference interviews and the realities of conducting clinical research in private practice. Tune in for a nuanced discussion on individualizing PDA management in the NICU!----Prophylactic Treatment of Patent Ductus Arteriosus With Acetaminophen: A Randomized Clinical Trial. Rozé JC, Cambonie G, Flamant C, Patkaï J, Mühlbacher T, Gascoin G, Rideau Batista Novais A, Tauzin M, Le Duc K, Beuchée A, Joye S, Babacheva E, Bouissou A, Ligi I, Tammela O, Plourde M, Dempsey E, Tosello B, Nguyen K, Vincent M, Andresson P, Binder C, Kruse C, Barcos Munoz F, Kuhn P, Proença E, Bartocci M, Kermorvant-Duchemin E, Nellis G, Lumia M, Giapros V, Rigo V, Sankilampi U, Mendes da Graça A, Rønnestad A, Soukka H, Mondì V, Aikio O, Torre-Monmany N, Rüegger C, Baud O, Zeitlin J, Morgan AS, Baruteau AE, Ancel PY, Carbajal R, Bouazza N, Diallo A, Levoyer L, Kemper R, Hallman M, Alberti C, Ursino M; TREOCAPA Study Group.JAMA Pediatr. 2026 Feb 16:e256150. doi: 10.1001/jamapediatrics.2025.6150. Online ahead of print.PMID: 41697673Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

On this episode, Bill Dupee, Partner, Transaction Advisory Services at Aprio, breaks down how buyers and sellers can use diligence to clarify the true economic engine of a business, identify risk early and build a narrative that stands up in a competitive process.Learn how disciplined metrics, higher-quality information and a repeatable diligence process shape deal outcomes, from avoiding late-stage surprises to accelerating post-close value creation. Plus, hear where deals most often falter and how better preparation changes both speed and leverage in negotiations.The information contained in this podcast is not intended to constitute, and should not be construed as, investment advice.

Review the latest clinical guidelines on LDL-C reduction, especially for your patients with diabetes. Guest Susan Halli Demeter, DNP, CNP, NP, also reflects on how engaging patients in shared decision-making aids in treatment adherence and identifies potential barriers to address, including polypharmacy, access, and other issues.References and Related Resources:PCNA Lipid resources for providers and patientsPCNA Diabetes resources for providers and patientsCARDS trialIMPROVE-IT trialFOURIER trialODYSSEY trialVESALIUS-CV trialSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After more than 20 years in practice, I've noticed there are certain treatment areas that consistently create change across a wide range of complaints. The key isn't the technique but understanding why these areas matter and when to address them.In this episode of the Unreal Results podcast, I share five treatment regions I find myself coming back to again and again across elite athletes, Navy SEAL candidates, and complex cases. These are high-payoff regions that consistently influence the body as a whole when addressed with intention.In this episode, you'll learn:How nerve pathways and fascial relationships explain why these areas matter far beyond local painWhy sequencing matters more than the tool you're usingHow to apply these concepts without overcomplicating your sessionsThis episode isn't about adding more techniques, it's about sharpening your ability to recognize the areas that matter most in each session.Resources & Links Mentioned In This Episode:Episode 9: Left Side Sciatica or Right Side Shoulder Pain?Episode 26: Sartorius B.I.G.Episode 28: The Power Of The Trigeminal NerveEpisode 70: How The Trigeminal Nerve Could Supercharge Your PracticeEpisode 73: The Sartorius: It's More Powerful Than You ThinkEpisode 86: Decoding The Nervous System For Health Pros Episode 142: The Most Overlooked Skill In Clinical PracticeTreatment Video: Superior Gluteal Nerve GlideTreatment Video: Manual Technique For Superior Gluteal NerveTreatment Video: Neural Manipulation Technique For Superior Gluteal NerveOnline Course: Go-To Treatments For The Viscera & Nervous SystemLearn the LTAP® In-Person in one of my upcoming coursesConsidering the viscera as a source of musculoskeletal pain and dysfunction is a great way to ensure a more true whole body approach to care, however it can be a bit overwhelming on where to start, which is exactly why I created the Visceral Referral Cheat Sheet. This FREE download will help you to learn the most common visceral referral patterns affecting the musculoskeletal system. Download it at www.unrealresultspod.com=================================================Watch the podcast on YouTube and subscribe!Join the MovementREV email list to stay up to date on the Unreal Results Podcast and MovementREV education. Be social and follow me:Instagram | Facebook | Twitter | YouTube

Cody Mansfield joins the show to unpack the real value of residency and fellowship training — and to share insights from his new Cardon Research Award–funded study examining outcomes in non-operative knee pain.Cody serves as Director of the Ohio State OMPT Fellowship, research associate, physical therapist, associate editor for JOSPT Cases, and instructor in the OSU DPT program. His mixed-methods research evaluates whether post-professional training changes outcomes related to quality, service, and cost — and what patients themselves value about receiving care from fellowship-trained clinicians.In this conversation: • Why this research matters for the future of OMPT • Early insights from comparing trained vs. non-trained clinicians • Patient perspectives on fellowship-trained PTs • Residency vs. fellowship — how they actually differ • Cody's educational sessions on LE referral patterns and spinal decision-making • His journey through a PhD while raising two young boysWhether you're a student, clinician, educator, or program director, this episode gives you a grounded look at what advanced training really does for patient care.

 Charles Gragg is an accomplished healthcare benefit solutions strategist, consultant, and author with over four decades of experience inside the American health insurance industry. Having worked in virtually every aspect of health insurance claims management, brokering, risk, and employer consulting, Charles is renowned for guiding CEOs and HR leaders to reclaim control over one of their company's largest operating expenses: employee health insurance. His bestselling book, “Get Off the Hamster Wheel: An Employer's Guide to Controlling His Second Largest Operating Expense,” is transforming how business owners approach group health plans for long-term savings and better employee outcomes. In this episode of Marketer of the Day, Charles joins Robert Plank to expose the myths and hidden costs plaguing employer health insurance. Drawing on his unique vantage point as an industry insider turned transparency advocate, Charles unpacks actionable strategies to shift from overpriced, opaque insurance models to self-funded, outcome-driven plans. He explains how employer ignorance, market consolidation, and entrenched carriers (“the cartel”) conspire to keep costs high and what leaders can do to fight back. Discussion covers stepping away from traditional carriers, hiring independent third-party administrators, leveraging technology and analytics, educating employees, and how reference-based pricing benchmarks real savings. Charles shares riveting success stories, practical challenges, and the essential mindset shift required for sustainable change. Quotes: “Employers must know where every dollar is going and I will account for it for you.” “The only way to control the cost is to control owning the business.” “You can't just keep doing what you've been doing and expect a different result. That's insanity.” Resources: Connect with  Charles Gragg on LinkedIn Grab “Get Off the Hamster Wheel” on Amazon.

There have been great advances in the treatment of cystic fibrosis, but nevertheless it remains a progressive, life‑shortening genetic disease as many patients still don't reach normal function and continue to face infections, exacerbations, and impaired quality of life. Siona Therapeutics is building a new generation of small‑molecule therapies that directly stabilize the region most affected by the most common mutation underlying the disease for the roughly 90 percent of patients who carry the defect. We spoke to Mike Cloonan, CEO of Sionna, about its experimental therapy that stabilizes the misfolded protein at the heart of the disease, its exploration of combination therapies with existing and proprietary therapies, and its $219 million IPO in February, despite the difficult financing environment for development-stage biotechs.

Today's episode is a re-air in support of Pods Fight Poverty, a campaign from our friends at GiveDirectly. You can learn more and donate at: GiveDirectly.org/Dimagi—-In this episode, we're joined by Stella Luk, Regional Director at GiveDirectly, and Erin Quinn, Dimagi's Senior Director of Customer Success, to explore a fundamental question: What if, instead of aid programs deciding what communities need, we simply gave people cash and trusted them to make the best choices for themselves?GiveDirectly has pioneered direct, unconditional cash transfers to people living in extreme poverty, challenging long-held assumptions about traditional aid. Stella shares powerful insights from the field—how cash empowers recipients with dignity, choice, and long-term impact. We also discuss the skepticism surrounding cash transfers, the evidence supporting their effectiveness, and how technology is helping reach those most in need.With global development funding in flux, could direct cash transfers be the future of aid? Listen in for a thought-provoking conversation on how this model is reshaping humanitarian response and development efforts worldwide.Related Resources: GiveDirectly.orgDebunking 5 myths about cash transfersKenya study comparing lump and flow study done by Abhijit BanerjeeUgandan youths given $382 earned 38% more 4 years laterRelated and referenced podcast episodes: The Journey to Scale: Lessons learned from supporting the largest digitally-enabled Frontline Worker program in the world with Kriti Mehrotra, Shayoni Mazumdar and Stella LukImproving Health Worker Jobs to Improve Outcomes with CommCare ConnectSign up to our newsletter⁠, and stay informed of Dimagi's workWe are on social media - follow us for the latest from Dimagi: ⁠LinkedIn⁠, ⁠Twitter⁠, ⁠Facebook⁠⁠⁠, ⁠Youtube⁠⁠⁠⁠If you enjoy this show, please leave us a 5-Star Review and share your favorite episodes with friends. Hosts: ⁠Jonathan Jackson⁠ and ⁠Amie Vaccaro

During the episode, MedCity News Associate Editor Katie Adams interviews Dr. Hamad Husainy, chief medical officer at PointClickCare, and Dr. Barbara Bond, a physician at Sutter Health, about how AI can help improve patient outcomes in the emergency department.   Episode Resources Connect with Arundhati Parmar aparmar@medcitynews.com  https://twitter.com/aparmarbb?lang=en https://medcitynews.com/   Review, Subscribe and Share If you like what you hear please leave a review by clicking here   Make sure you're subscribed to the podcast so you get the latest episodes. Click here to subscribe with Apple Podcasts  Click here to subscribe with Spotify Click here to subscribe with Podbean Click here to  

Join us for this insightful and inspiring discussion with a true literacy hero Margaret Goldberg, co-founder of The Right to Read Project. During this podcast, we'll talk with Goldberg about the next step in the science of reading movement: Educators moving from research consumers to active research participants. While there's been progress bringing research awareness to classrooms, we now face a moment where the future of reading science depends on practitioner involvement.This episode examines how educators have moved from implementing prescribed practices to actively seeking evidence-based approaches, and why this momentum can't stagnate. With uncertain federal support for education research, we must bridge the “last mile” between research and practice—the phase that matters most to students and teachers.Drawing from personal experiences, this episode reveals what it means to move from research consumer to research contributor, including the moments that change how educators view and engage with scientific evidence. We'll discuss research-to-practice partnerships and how thinking like a scientist can change classroom implementation.Listeners will learn:Where the science of reading movement stands todayWhy this isn't another pendulum swing in educationThe importance of bridging the “last mile” between research and practiceWhat it feels like to move from research consumer to active participantPractical steps for joining research-to-practice partnershipsHow to approach classroom implementation with a scientific mindsetWhy practitioner involvement is essential for sustaining progressStrategies for participating in scienceEssential listening for educators, administrators, and literacy advocates ready to help shape the future of reading instruction and ensure research continues to benefit students in classrooms.

Today's topic on palliative care for sickle cell disease may raise eyebrows with some of you.  You might think, wait, now we're doing sickle cell?  On top of liquid cancer and transplant, kidney disease, liver disease, and survivorship?  Where does it end?  Do we have staff for all of this? Well I implore you, dear listeners, to keep an open mind and listen to this podcast.  Our guests do a fabulous job of stating the case for palliative care in sickle cell disease, to the point that we ask: why haven't we been doing this all along? Our guests today are Craig Blinderman, Stephanie Kiser, Eberechi Nwogu-Onyemkpa, three palliative care docs who have been advancing the practice in palliative care for sickle cell for a long time. Our discussion ranges from what is sickle cell; to outcomes; to social determinants and discrimination; to PCAs, ketorolac, and bupenorphine; and to the importance of the interdisciplinary team. I would also encourage you to check out Eberechi's NEJM Perspective on Involving Palliative Care to Improve Outcomes in Sickle Cell, which includes a table of the challenges and action items needed to move the field forward. I'd also encourage you to sample this AAHPM Flight on the same topic (we learned that a flight is similar to a flight of drinks - a quick sampling). As Eberechi notes at the start, we should be grateful for the community of people who are advancing palliative care in sickle cell.  Thank you for being a friend (song hint!). -Alex Smith  

Eberechi Nwogu-Onyemkpa is an assistant professor in the Division of Palliative Medicine at Washington University in St. Louis. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E. Nwogu-Onyemkpa and Others. Involving Palliative Care to Improve Outcomes in Sickle Cell Disease. N Engl J Med 2025;393:1553-1556. E. Costa and Others. Thirty Years of Hydroxyurea for Sickle Cell Anemia — Scientific Progress, Global Health Gaps. N Engl J Med 2025;393:1556-1559.

Send us a textEffect of enteral supplementation of DHA with or without ARA in preterm infants: a meta-analysis.Dang D, Gao Z, Zhang C, Mu X, Lv X, Wu H.Arch Dis Child Fetal Neonatal Ed. 2025 Apr 15:fetalneonatal-2024-327606. doi: 10.1136/archdischild-2024-327606. Online ahead of print.PMID: 40233974Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

As the shortage of primary care doctors continues, the job market is on the upswing for advanced practice providers.According to the Bureau of Labor Statistics, employment for nurse practitioners is projected to grow by 40% between 2024 and 2034, making it one of the fastest-growing professions in the country.Physician assistants aren't far behind -- projected to grow 20% over the next ten years.WXXI's health, equity, and community reporter, Racquel Stephen, hosts the show, where she and her panel of experts discuss the responsibilities and employment outlook for these jobs, and examine legislation that proposes more independence for these health care professionals.Our guests: Heather Grotke, department chair and director of Nazareth University's physician assistant program Duncan Wersinger, senior director, advanced practice for Rochester Regional Health Bonnie Walden, clinical associate professor and chair of Nazareth University's Nursing Department ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

In this episode, we explore the intersection of storytelling and science. Join us as we dive into Eva's Itchy Adventure, a children's book created to help kids living with eczema better understand and manage their condition. We'll discuss the concept of bibliotherapy—using books as a therapeutic tool—and how it can improve outcomes by reducing anxiety, empowering patients, and strengthening connections between families and healthcare providers.Books referenced in this episode:Ezra'sItchy Red SkinAli'sHair LossSoaringHigh: A Children's Book about PsoriasisYour Skin is ShowingUpdates:PeDRA Annual ConferenceDash for DiscoveryEmerging Investigator Research Grants Program Career Bridge Research Grant Consensus Grant ProgramPediatric Ichthyosis Challenge Grant SOCS Scientific Symposium

Physician's Weekly board member Alex McDonald, MD, and Stephanie Sutherland, PhD, continue their discussion about science...

Physician's Weekly board member Alex McDonald, MD, and Stephanie Sutherland, PhD, continue their discussion about science communication, emphasizing the importance of empowering patients through health literacy.Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Physician's Weekly board member Alex McDonald, MD, returns to talk with medical writer Stephanie Sutherland, PhD, about the...

Physician's Weekly board member Alex McDonald, MD, returns to talk with medical writer Stephanie Sutherland, PhD, about the critical need for effective science communication with patients.Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

Routine vaginal examinations (VEs) are a standard component of intrapartum care, traditionally performed at regular intervals to monitor cervical dilation, effacement, and fetal station, which are indicators of labor progression. Yet, the American College of Obstetricians and Gynecologists states that there is insufficient evidence to recommend a specific frequency for cervical examinations during labor, and examinations should be performed as clinically indicated. Now, a recently published RCT form AJOG MFM is adding additional credence to that. Can we space out clinical exams in otherwise “low-risk” laboring women to 8 hours? Listen in for details. 1. AJOG MFM: (08/18/25) Routine Vaginal Examination Scheduled At 8 vs 4 Hours In Multiparous Women In Early Spontaneous Labour: A Randomised Controlled Trial https://www.sciencedirect.com/science/article/abs/pii/S25899333250016122. Nashreen CM, Hamdan M, Hong J, et al.Routine Vaginal Examination to Assess Labor Progress at 8 Compared to 4 h After Early Amniotomy Following Foley Balloon Ripening in the Labor Induction of Nulliparas: A Randomized Trial. Acta Obstetricia Et Gynecologica Scandinavica. 2024;103(12):2475-2484. doi:10.1111/aogs.14975.3. First and Second Stage Labor Management: ACOG Clinical Practice Guideline No. 8. Obstetrics and Gynecology. 2024;143(1):144-162. doi:10.1097/AOG.0000000000005447.4. Moncrieff G, Gyte GM, Dahlen HG, et al. Routine Vaginal Examinations Compared to Other Methods for Assessing Progress of Labour to Improve Outcomes for Women and Babies at Term. The Cochrane Database of Systematic Reviews. 2022;3:CD010088. doi:10.1002/14651858.CD010088.pub3.5. Gluck, O., et al. (2020). The correlation between the number of vaginal examinations during active labor and febrile morbidity, a retrospective cohort study. [BMC Pregnancy and Childbirth]6. Pan, WL., Chen, LL. & Gau, ML. Accuracy of non-invasive methods for assessing the progress of labor in the first stage: a systematic review and meta-analysis. BMC Pregnancy Childbirth 22, 608 (2022). https://doi.org/10.1186/s12884-022-04938-y

This week, Kelly shares a powerful, research-driven strategy that she developed—almost by accident—that has become a game-changer in her therapy room and for countless SIS members.

The U.S. ranks worst among developed nations for maternal and child health outcomes, highlighting a systemic failure that demands urgent attention. In this episode, Rebekah Gee examines the crisis of maternal mortality in the U.S. and how structural inequities and lack of home-based care continue to harm vulnerable families, drawing on her own life experiences and leadership in Medicaid expansion. She introduces Nest Health, a holistic, home-based model that serves entire Medicaid households, aiming to reduce ER visits, improve outcomes, and rebuild trust through empathy, data, and community-rooted care. Tune in and learn how innovation, policy, and persistence can reshape health care from the ground up! Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. John Guercio returns to the Behavioral Observations Podcast for his third appearance, bringing his extensive experience and fresh insights into the world of adult services in behavior analysis. In this episode, John and Matt discuss the vital, yet often overlooked, field of supporting adults with autism and other developmental disabilities—particularly those with severe behavioral challenges. They explore: John's new leadership role at The Arc of the Ozarks The Applied Behavior Analysis Center The development of a new adult-specific RBT training program His latest book on staff training in adult service settings Key findings from his recent research on enhancing data collection in residential facilities The systemic and practical challenges of working in group homes and ISLs Throughout the conversation, Dr. Guercio emphasizes the importance of dignity, choice, and inclusion, and provides practical strategies for training and retaining staff who work in high-demand settings.

A groundbreaking new study confirms the benefits of coronary artery calcium (CAC) scoring in asymptomatic individuals, reinforcing the case for routine CT scans starting at age 40. This week, Dr. Kahn breaks down the findings and what they mean for heart health. Other topics include: The health benefits of dietary niacin and how it supports overall wellness. New research showing plant oils are a healthier choice than butter for heart and cancer outcomes.